Merck Dirección

Dirección controles de criterios 3/4

El CEO de Merck es Rob Davis , nombrado en Apr 2021, tiene una permanencia de 3.58 años. compensación anual total es $20.27M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.014% de las acciones de la empresa, por valor de CHF30.57M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 5.2 años, respectivamente.

Información clave

Rob Davis

Chief Executive Officer (CEO)

US$20.3m

Compensación total

Porcentaje del salario del CEO	7.9%
Permanencia del CEO	3.6yrs
Participación del CEO	0.01%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rob Davis en comparación con los beneficios de Merck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

Compensación vs. Mercado: La compensación total de Rob($USD20.27M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD4.75M).

Compensación vs. Ingresos: La compensación de Rob ha sido consistente con los resultados de la empresa en el último año.

CEO

Rob Davis (57 yo)

3.6yrs

Permanencia

US$20,273,287

Compensación

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	3.6yrs	US$20.27m	0.014% CHF 30.6m
Caroline Litchfield	Executive VP & CFO	3.6yrs	US$8.30m	0.0020% CHF 4.5m
Richard DeLuca	Executive VP & President of Merck Animal Health	13.2yrs	US$6.20m	0.0060% CHF 13.3m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	15yrs	US$6.24m	0.0062% CHF 13.8m
Dean Li	Executive VP & President of Merck Research Laboratories	7yrs	US$9.78m	0.0018% CHF 4.1m
Dalton Smart	Senior VP of Finance	less than a year	sin datos	0.00018% CHF 399.6k
David Williams	Executive VP and Chief Information & Digital Officer	no data	sin datos	0.00079% CHF 1.8m
Peter Dannenbaum	Vice President of Investor Relations	5.3yrs	sin datos	sin datos
Jennifer Zachary	Executive VP & General Counsel	6.6yrs	US$5.90m	0.0012% CHF 2.6m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.3yrs	sin datos	sin datos
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	sin datos	sin datos
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	3.8yrs	sin datos	0.00094% CHF 2.1m

3.8yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 010683053 se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	3.3yrs	US$20.27m	0.014% CHF 30.6m
Pamela Craig	Independent Director	9.2yrs	US$400.00k	0.000070% CHF 155.4k
Patricia Russo	Independent Director	29.2yrs	US$360.00k	0.00052% CHF 1.2m
Thomas Glocer	Independent Lead Director	17yrs	US$430.10k	0.00020% CHF 444.0k
Risa Lavizzo-Mourey	Independent Director	4.5yrs	US$365.00k	0.000040% CHF 88.8k
Douglas Baker	Independent Director	2.5yrs	US$347.64k	0.000040% CHF 88.8k
Inge Thulin	Independent Director	6.7yrs	US$340.00k	0% CHF 0
Stephen Mayo	Independent Director	3.7yrs	US$350.00k	0% CHF 0
Kathy Warden	Independent Director	4.7yrs	US$350.00k	0.000020% CHF 44.4k
Christine Seidman	Independent Director	4.7yrs	US$350.00k	0% CHF 0
Paul Rothman	Independent Director	9.2yrs	US$380.00k	0% CHF 0
Mary Coe	Independent Director	5.7yrs	US$342.36k	0% CHF 0

5.2yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 010683053 se considera experimentada (5.2 años de antigüedad promedio).

Merck Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Recent updates

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Insufficient new directors

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Second quarter 2024 earnings released: EPS: US$2.14 (vs US$2.35 loss in 2Q 2023)

First quarter dividend of US$0.77 announced

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad